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Background: Results of previous influenza vaccination effects on current season in-
fluenza vaccine effectiveness (VE) are inconsistent.
Objectives: To explore previous influenza vaccination effects on current season VE 
among population targeted for vaccination.
Methods: We used 2011/2012 to 2016/2017 I- MOVE primary care multicentre test- 
negative data. For each season, we compared current season adjusted VE (aVE) be-
tween individuals vaccinated and unvaccinated in previous season. Using unvaccinated 
in both seasons as a reference, we then compared aVE between vaccinated in both 
seasons, current only, and previous only.
Results: We included 941, 2645 and 959 influenza- like illness patients positive for 
influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 
2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those 
vaccinated	in	previous	season	were	−68%,	−21%	and	−19%,	respectively;	among	un-
vaccinated	in	previous	season,	these	were	33%,	48%	and	46%,	respectively	(aVE	not	
computable for influenza A(H1N1)pdm09 and B). Compared to current season vacci-
nation only, VE for both seasons’ vaccination was (i) similar in two of four seasons for 
A(H3N2)	(absolute	difference	[ad]	6%	and	8%);	(ii)	lower	in	three	of	four	seasons	for	
influenza	 A(H1N1)pdm09	 (ad	 18%,	 26%	 and	 29%),	 in	 two	 seasons	 for	 influenza	
A(H3N2)	(ad	27%	and	39%)	and	in	two	of	three	seasons	for	influenza	B	(ad	26%	and	
37%);	(iii)	higher	in	one	season	for	influenza	A(H1N1)pdm09	(ad	20%)	and	influenza	B	
(ad	24%).
Conclusions: We did not identify any pattern of previous influenza vaccination effect. 
Prospective cohort studies documenting influenza infections, vaccinations and vac-
cine types are needed to understand previous influenza vaccinations’ effects.
K E Y W O R D S
case-control study, influenza, influenza vaccine, multicentre study, vaccine effectiveness
1  | INTRODUC TION
Constant evolution of influenza viruses requires possible refor-
mulation of the influenza vaccine every season. In February each 
year, the World Health Organization (WHO) organises a technical 
consultation to decide which influenza strains to be included in the 
Northern Hemisphere seasonal influenza vaccines.1
Most groups for whom the seasonal influenza vaccine is recom-
mended may receive a trivalent or quadrivalent inactivated seasonal 
influenza vaccine annually irrespective of their previous influenza 
virus infections or influenza vaccination history. In children less 
than 9 years old, one dose of inactivated influenza vaccine is recom-
mended for children vaccinated in previous season and two doses 
for those previously unvaccinated.2
Several observational studies and meta- analyses have reported 
inconsistent results of the effect of previous vaccination on current 
season influenza vaccine effectiveness (VE).3-12 Some suggest that 
previous vaccination may reduce the effectiveness of vaccination 
in the current season.3,5,6 Various explanations were proposed. The 
original “antigenic sin” hypothesis suggests that vaccination primar-
ily boosts pre- existing antibody responses that cross- react with 
the vaccine strain rather than producing a de novo response to the 
vaccine or infecting strain.13 The “antibody block” hypothesis sug-
gests that previously vaccinated individuals do not have the cross- 
protective immunity provided by natural infection.14,15 According to 
the “antigenic distance” hypothesis, in seasons when similar strains 
are included in the subsequent vaccines but are different from the 
circulating strain, previous vaccination may negatively interfere 
with current vaccination.16 Finally, because the influenza vaccine is 
recommended to individuals with high- risk conditions (eg pregnant 
women, persons with chronic conditions, older adults aged >59 or 
>64 years), characteristics of individuals repeatedly vaccinated may 
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result in a poorer observed response to the vaccine if we fail to con-
trol for negative confounding.4
Due to the frequent changes of the genetic and antigenic charac-
teristics of the circulating influenza strains and of those included in 
the vaccines, data from multiple seasons are needed to measure the 
potential effects of previous vaccinations and to explore the possi-
ble mechanism(s) that may explain such effects.11
In this article, using the I- MOVE primary care multicentre case- 
control study (MCCS) data, we present influenza type- /subtype- 
specific VE stratified by previous season vaccination among 
the target groups for vaccination for each of the 2011/2012 to 
2016/2017 seasons. Additionally, using those unvaccinated in both 
seasons as a reference group, we calculated VE for different combi-
nations of previous/current vaccination among the target population 
for vaccination (indicator analysis).
Both analyses measure the effect of current vaccination among 
those not vaccinated in the previous season. The indicator analysis 
additionally gives information on the potential residual protection 
of the previous season vaccination and the combined protection of 
current and previous season vaccination, compared to the reference 
group. This reference group “unvaccinated in both seasons” may 
consist of a population that is quite different from the other catego-
ries of individuals who have been vaccinated, making controlling for 
confounding challenging.11 Therefore, we present also the stratified 
analysis, where the stratum of those with previous vaccination indi-
cates the extra protection the current vaccination may have, com-
pared to residual effects of previous vaccination, while controlling 
adequately for previous vaccination history.
2  | METHODS
Each season we conducted a primary care–based test- negative de-
sign MCCS. The methods were described previously and are based 
on the same generic study protocol.17
In summary, practitioners from twelve participating sites inter-
viewed a systematic sample of patients consulting for influenza- like 
illness (ILI; EU case definition18: sudden onset of symptoms and at 
least one of the following systemic symptoms: fever or feverishness, 
malaise, headache, myalgia and at least one of the following respi-
ratory symptoms: cough, sore throat, shortness of breath) and col-
lected nasopharyngeal specimens for virological analyses. The data 
collected include ILI symptoms and date of onset, age, sex, presence 
of chronic conditions and hospitalisation for the chronic conditions 
in the previous 12 months.
Vaccination status for current (including date of vaccination and 
type of vaccine used) and previous season were documented either 
through patients’ self- report or extracted from practitioners’ vac-
cine registries.
We defined patients as vaccinated in the current season if 
they had received at least one dose of influenza vaccine more than 
14 days before symptom onset. All others with information on 
current vaccination status were defined as unvaccinated. Patients 
who received at least one dose of influenza vaccine in the previous 
season were defined as vaccinated in the previous season. For this 
analysis, we used the population for which influenza vaccination is 
recommended every season, as they are likely to be a more homoge-
neous group in terms of vaccination practices than those for whom 
vaccination is not recommended. They include older adults (aged 
over 54, 59 or 64 years depending on study site), individuals with 
chronic conditions and, where available, other groups for whom the 
vaccine was recommended in a given country (eg pregnant women, 
healthcare workers and other professional groups, depending on the 
study site). We excluded children aged less than 9 years as the defi-
nition of their current season vaccination status depends on their 
previous season vaccination.
Cases were ILI patients testing positive for any type- /subtype- 
specific influenza virus using real- time reverse- transcription PCR 
(RT- PCR). Controls were those testing negative for all influenza 
viruses.
Study periods depended upon season- and site- specific influ-
enza virus type/subtype circulation and vaccination campaigns.
We included ILI patients who consulted their practitioner more 
than 14 days after the start of national or regional seasonal influenza 
vaccination campaign, who were swabbed less than 8 days after ILI 
symptom onset and who did not receive influenza antivirals before 
swabbing. We excluded patients with missing information for cur-
rent or previous season vaccination status.
We used logistic regression to compute the odds ratio (OR) of being 
vaccinated in cases and controls. We estimated the type- /subtype- 
adjusted	 influenza	VE	as	 (1	−	OR)*100.	Study	site	was	modelled	as	a	
fixed effect and always included in the crude and adjusted analysis 
models. We measured VE carrying out a complete case analysis exclud-
ing patients with missing values for any of the variables in the model 
measuring VE. We included age, sex, presence of chronic conditions, 
pregnancy and obesity, where applicable, and date of symptom onset 
as a priori confounding variables in the model. All other potential con-
founders were included in the model if they changed the VE point esti-
mate	by	5%	(absolute	percentage).	Age	and	onset	time	were	modelled	
as a restricted cubic spline with knots specified according to Harrel.19
We measured current season VE for each type/subtype and sea-
son. To study the effects of previous vaccination on current season 
vaccination, we conducted two analyses.
First, we conducted a stratified analysis in which we measured 
current season VE among individuals vaccinated and unvaccinated 
in the previous season.
In a second analysis, we used unvaccinated in both seasons as a 
reference to compare VE between vaccinated in current season only, 
vaccinated in previous season only and vaccinated in both seasons, 
using a mutually exclusive indicator variable. We refer to this analy-
sis as the indicator analysis.
For each influenza type/subtype, we used seasons and sites for 
which I- MOVE MCCS included at least four cases of this influenza 
type/subtype per analysed stratum. We deemed sample size too 
small to attempt an analysis if there were fewer than 50 cases in the 
pooled study analysis. If the 10 events per variable (EPV) rule was 
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violated,20 we carried out a sensitivity analysis using Firth’s method 
of penalised logistic regression to check for small sample bias.
3  | RESULTS
3.1 | Recruitment
From season 2011/2012 to 2016/2017, we included between 6 (in 
2013/2014) and 12 (in 2015/2016, 2016/2017) sites in the pooled 
analysis of our multicentre study (Table 1). GPs enrolled 10 831 ILI 
patients, aged 9 years or older, belonging to the groups targeted 
for influenza vaccination. Of these, we excluded 368 individuals 
with missing information on current season vaccination and 405 on 
previous vaccination. The proportion of individuals excluded due to 
missing	information	on	current	or	previous	season	was	6.9%	among	
cases	and	7.3%	among	controls	(Fisher’s	exact	test,	P = .365). The 
median age was 63 and 60 years for those with missing and com-
plete information for vaccination status, respectively (P < .001).
Of the 10 058 ILI individuals with information on current and 
previous	 season	 vaccination	 status,	 19	 (0.2%)	 had	 influenza	 virus	
coinfections reported and were considered in more than one influ-
enza	 type/subtype	 analyses.	We	 therefore	 included	 5532	 (54.9%)	
ILI	patients	negative	 for	all	 influenza	viruses	and	941	 (9.3%),	2645	
(26.2%)	and	959	(9.5%)	positive	for	influenza	virus	A(H1N1)pdm09,	
A(H3N2) and B, respectively (Table 2).
The median age was 54, 55, 63 and 61 years among influenza 
A(H1N1)pdm09, influenza B cases, influenza A(H3N2) cases and 
controls, respectively.
The proportion of vaccinated with current season vaccine was 
32%	 among	 controls	 and	 20%,	 31%	 and	 21%	 among	 influenza	
A(H1N1)pdm09, A(H3N2) and B cases, respectively (Table 2). The 
proportion of quadrivalent vaccines used among those with known 
vaccine	brand	was	<1%.
In	each	analysis,	 among	cases	and	controls,	 less	 than	6%	were	
vaccinated	in	the	current	season	only	and	less	than	8%	in	the	previ-
ous	season	only.	More	than	60%	of	cases	and	controls	were	unvac-
cinated	in	both	current	and	previous	season	and	less	than	27%	were	
vaccinated in both seasons (Table 2).
The proportion of controls 65 years and older among those vacci-
nated	in	both	seasons	was	64.3%	compared	to	44.2%,	42.0%	and	27.1%	
among those vaccinated in the previous season only, vaccinated in the 
current season only and not vaccinated in either season (Table 3).
3.2 | Vaccine effectiveness
We included four influenza seasons for the influenza A(H1N1)pdm09 
and A(H3N2) analysis and two for the influenza B analysis (Table 4).
3.2.1 | Current season VE
The current season adjusted VE against influenza A(H1N1)pdm09 
ranged	from	33%	(95%	CI:	10-	51)	in	2015/2016	to	56%	(95%	CI:	22-	
75) in 2013/2014.
Current season VE against influenza A(H3N2) ranged from 
16%	 (95%	 CI:	 −10	 to	 36)	 in	 2014/2015	 to	 38%	 in	 2013/2014	
(95%	CI:	−1	to	62),	and	against	B,	 it	 ranged	from	20%	(95%	CI:	
−14	 to	 43)	 in	 2015/216	 to	 51%	 (95%	CI:	 27-	68)	 in	 2012/2013	
(Table 1).
3.2.2 | Stratified analysis, current season VE 
according to previous season vaccination
Influenza A(H1N1)pdm09
Among those not vaccinated in the previous season, the cur-
rent	season	adjusted	VE	ranged	from	51%	(95%	CI:	−29	to	81)	 in	
2013/2014	 to	63%	 (95%	CI:	6-	85)	 in	2015/2016.	We	could	only	
compute current season adjusted VE among those vaccinated in 
the previous season for one season due to the high proportion of 
individuals vaccinated in both current and previous season. In the 
2015/2016 season, the VE against A(H1N1)pdm09 among those 
vaccinated	in	the	previous	season	was	−38%	(95%	CI:	−179	to	31)	
(Table 1).
Influenza A(H3N2)
We could compute VE stratified by previous vaccination status 
in three of the four seasons. In these three seasons, current sea-
son VE point estimate among those vaccinated in previous season 
was	 negative	 (−68%,	 −21%	 and	 −19%	 in	 2011/2012,	 2014/2015,	
2016/2017, respectively) and lower than among those unvaccinated 
in	previous	season	 (33%,	48%	and	46%	 in	2011/2012,	2014/2015	
and 2016/2017, respectively) (Table 1).
Influenza B
Among those not vaccinated in previous season, current season ad-
justed	VE	 ranged	 from	43%	 (95%	CI:	−34	 to	76)	 in	2012/2013	 to	
61%	(95%	CI:	20-	81)	in	2014/2015.	The	current	season	VE	among	
those	vaccinated	in	the	previous	season	ranged	from	34%	to	48%	
(Table 1).
3.2.3 | Indicator analysis, using those unvaccinated 
in both seasons as reference
Influenza A(H1N1)pdm09
In 2013/2014, the VE point estimate for vaccination in both current 
and previous seasons was higher than that for vaccination in the 
current season only (Table 5). In the other three seasons, VE point 
estimates for vaccination in both seasons were lower than those 
for vaccination in current season only. VE point estimates for vac-
cination	 in	previous	season	only	were	35%	 in	2014/2015	and	47%	
in 2015/2016 and negative in both 2012/2013 and 2013/2014 
(Table 5).
Influenza A(H3N2)
In 2013/2014, 2014/2015 and 2016/2017, VE point estimates 
for vaccination in both current and previous seasons were lower 
than those for vaccination in current season only (Table 5). In 
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TABLE  2 Characteristics for influenza A(H1N1)pdm09, A(H3N2) and influenza B cases and controls belonging to the target group for 
influenza vaccination, aged 9 y or older, I- MOVE 2011/2012- 2016/2017
Characteristics
Number of test- negative 
controlsa/total n (%)
Number of influenza A(H1N1)pdm09 
casesb,c/total n (%)
Number of influenza A(H3N2) 
casesb,d/total n (%)
Number of influenza B 
casesc,d/total n (%)
Median age (y) 61.0 54.0 63.0 55.0
 Missing 14 5 4 8
Age groups
 9- 14 194/5518 (3.5) 33/936 (3.5) 130/2641 (4.9) 97/951 (10.2)
 15- 64 3183/5518 (57.7) 662/936 (70.7) 1333/2641 (50.5) 572/951 (60.1)
	≥65 2141/5518 (38.8) 241/936 (25.7) 1178/2641 (44.6) 282/951 (29.7)
Sex
 Female 3249/5515 (58.9) 533/935 (57.0) 1469/2637 (55.7) 511/955 (53.5)
 Missing 17 6 8 4
Days between onset of symptoms and swabbing
 0 315/5532 (5.7) 26/941 (2.8) 108/2645 (4.1) 29/959 (3.0)
 1 1552/5532 (28.1) 311/941 (33) 874/2645 (33) 245/959 (25.5)
 2 1519/5532 (27.5) 312/941 (33.2) 847/2645 (32) 301/959 (31.4)
 3 1006/5532 (18.2) 163/941 (17.3) 493/2645 (18.6) 227/959 (23.7)
 4- 7 1140/5532 (20.6) 129/941 (13.7) 323/2645 (12.2) 157/959 (16.4)
Current season influenza vaccination
 Not vaccinated 
or vaccinated 
<15 d before 
ILI onset
3771/5532 (68.2) 749/941 (79.6) 1820/2645 (68.8) 759/959 (79.1)
 Vaccinated 1761/5532 (31.8) 192/941 (20.4) 825/2645 (31.2) 200/959 (20.9)
Previous season influenza vaccination
 Not vaccinated 
in current and 
previous 
season or 
vaccinated in 
current season 
<15 d before 
onset
3386/5532 (61.2) 708/941 (75.2) 1708/2645 (64.6) 704/959 (73.4)
 Current season 
vaccination 
only
324/5532 (5.9) 27/941 (2.9) 116/2645 (4.4) 30/959 (3.1)
 Previous 
season 
vaccination 
only
385/5532 (7.0) 41/941 (4.4) 112/2645 (4.2) 55/959 (5.7)
 Current and 
previous 
season 
vaccination
1437/5532 (26.0) 165/941 (17.5) 709/2645 (26.8) 170/959 (17.7)
Seasonal vaccination type
 Not vaccinated 
or vaccinated 
<15 d before 
onset
3771/5532 (68.2) 749/941 (79.6) 1820/2645 (68.8) 759/959 (79.1)
 Egg- derived 
inactivated 
subunit
521/5532 (9.4) 61/941 (6.5) 244/2645 (9.2) 69/959 (7.2)
(Continues)
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Characteristics
Number of test- negative 
controlsa/total n (%)
Number of influenza A(H1N1)pdm09 
casesb,c/total n (%)
Number of influenza A(H3N2) 
casesb,d/total n (%)
Number of influenza B 
casesc,d/total n (%)
 Egg- derived 
inactivated 
split virion
638/5532 (11.5) 97/941 (10.3) 309/2645 (11.7) 68/959 (7.1)
 Adjuvanted 351/5532 (6.3) 8/941 (0.9) 149/2645 (5.6) 17/959 (1.8)
 Cell- derived 
inactivated 
subunit
10/5532 (0.2) 0/941 (0.0) 7/2645 (0.3) 3/959 (0.3)
 Live attenuated 
influenza 
vaccine
0/5532 (0.0) 0/941 (0.0) 1/2645 (0.0) 0/959 (0.0)
 Unknown 
vaccine type
241/5532 (4.4) 26/941 (2.8) 115/2645 (4.3) 43/959 (4.5)
At least one 
chronic 
condition
4105/5436 (75.5) 699/931 (75.1) 1858/2612 (71.1) 700/945 (74.1)
 Missing 96 10 33 14
At least one 
hospitalisation 
in the previous 
12 mo for 
chronic 
conditions
352/5075 (6.9) 48/834 (5.8) 128/2462 (5.2) 51/841 (6.1)
 Missing 457 107 183 118
Study sites
 Croatia 100/5532 (1.8) 14/941 (1.5) 60/2645 (2.3) 18/959 (1.9)
 France 524/5532 (9.5) 126/941 (13.4) 390/2645 (14.7) 168/959 (17.5)
 Germany 1397/5532 (25.3) 173/941 (10.3) 505/2645 (19.1) 186/959 (19.4)
 Hungary 949/5532 (17.2) 33/941 (2.0) 276/2645 (10.4) 47/959 (4.9)
 Ireland 222/5532 (4) 65/941 (4.2) 130/2645 (4.9) 52/959 (5.4)
 Italy 476/5532 (8.6) 50/941 (3.3) 222/2645 (8.4) 56/959 (5.8)
 Poland 340/5532 (6.1) 70/941 (4.8) 116/2645 (4.4) 59/959 (6.2)
 Portugal 402/5532 (7.3) 95/941 (6.7) 175/2645 (6.6) 55/959 (5.7)
 Romania 179/5532 (3.2) 74/941 (5.5) 82/2645 (3.1) 53/959 (5.5)
 Spain 652/5532 (11.8) 197/941 (9.8) 592/2645 (22.4) 240/959 (25.0)
 Sweden 113/5532 (2) 8/941 (0.4) 43/2645 (1.6) 13/959 (1.4)
 The 
Netherlands
178/5532 (3.2) 36/941 (2.0) 54/2645 (2.0) 12/959 (1.3)
Season
 2011- 2012 600/5532 (10.8) - 411/2645 (15.5) - 
 2012- 2013 517/5532 (9.3) 181/941 (19.2) 114/2645 (4.3) 313/959 (32.6)
 2013- 2014 425/5532 (7.7) 123/941 (13.1) 153/2645 (5.8) - 
 2014- 2015 988/5532 (17.9) 174/941 (18.5) 608/2645 (23.0) 324/959 (33.8)
 2015- 2016 1357/5532 (24.5) 463/941 (49.2) - 322/959 (33.6)
 2016- 2017 1645/5532 (29.7) - 1359/2645 (51.4) - 
aControls from “any influenza” analysis used.
bOne influenza case coinfected for both influenza A(H3N2) and influenza A(H1N1)pdm09 was included in the analysis.
cNine influenza cases coinfected for both influenza B and influenza A(H1N1)pdm09 were included in the analysis.
dNine influenza cases coinfected for both influenza B and influenza A(H3N2) were included in the analysis.
TABLE  2  (Continued)
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2011/2012, VE point estimates for those two groups were simi-
lar	 (less	 than	 9%	 absolute	 difference).	 VE	 point	 estimates,	 for	
vaccination	 in	 previous	 season	 only,	 ranged	 from	 15%	 to	 60%	
(Table 5).
Influenza B
In 2012/2013, the VE point estimate for vaccination in both current 
and previous seasons was higher than that for vaccination in current 
season only. In 2014/2015 and 2015/2016, VE point estimates for 
vaccination in both seasons were lower than those for vaccination 
in the current season only. VE point estimates for vaccination in the 
previous	season	only	were	4%	 in	2012/2013	and	negative	 for	 the	
other two seasons (Table 5).
3.2.4 | Sensitivity analysis
Where the EPV was <10, penalised and standard logistic regression 
VE	estimates	did	not	differ	by	more	than	6.5%	absolute,	with	an	av-
erage	of	3.4%,	for	both	the	stratified	and	indicator	analyses,	indicat-
ing little bias due to sparse data.
4  | DISCUSSION
Our results suggest that, based on the stratified analysis results, 
previous vaccination may have an effect on current season VE 
among the population targeted for influenza vaccination. Despite 
TABLE  3 Characteristics of test- negative controlsa by vaccination history, among the target population for influenza vaccination, aged 9 y 
or more, I- MOVE 2011/2012- 2016/2017
Characteristics
Not vaccinated in either 
current or previous season
Vaccinated in 
current season
Vaccinated in previous 
season only
Vaccinated in 
both seasons
Median age (y) 56.0 62.0 62.0 69.0
 Missing 11 0 0 3
Age groups
 9- 14 153/3375 (4.5) 10/324 (3.1) 8/385 (2.1) 23/1434 (1.6)
 15- 64 2307/3375 (68.4) 178/324 (54.9) 207/385 (53.8) 491/1434 (34.2)
	≥65 915/3375 (27.1) 136/324 (42.0) 170/385 (44.2) 920/1434 (64.2)
 Missing 11 0 0 3
Sex
 Female 1396/3373 (41.4) 128/324 (39.5) 159/385 (41.3) 583/1433 (40.7)
 Male 1977/3373 (58.6) 196/324 (60.5) 226/385 (58.7) 850/1433 (59.3)
 Missing 13 0 0 4
Days between onset of symptoms and swabbing
 0 212/3386 (6.3) 17/324 (5.2) 17/385 (4.4) 69/1437 (4.8)
 1 1021/3386 (30.2) 89/324 (27.5) 105/385 (27.3) 337/1437 (23.5)
 2 958/3386 (28.3) 76/324 (23.5) 109/385 (28.3) 376/1437 (26.2)
 3 582/3386 (17.2) 59/324 (18.2) 63/385 (16.4) 302/1437 (21.0)
 4- 7 613/3386 (18.1) 83/324 (25.6) 91/385 (23.6) 353/1437 (24.6)
At least one chronic condition 2425/3315 (73.2) 253/317 (79.8) 308/380 (81.1) 1119/1424 (78.6)
 Missing 71 7 5 13
At least one hospitalisation in the 
previous 12 mo for chronic conditions
171/3104 (5.5) 20/294 (6.8) 33/346 (9.5) 128/1331 (9.6)
 Missing 282 30 39 106
Season
 2011- 2012 351/3386 (10.4) 39/324 (12.0) 42/385 (10.9) 168/1437 (11.7)
 2012- 2013 325/3386 (9.6) 24/324 (7.4) 37/385 (9.6) 131/1437 (9.1)
 2013- 2014 258/3386 (7.6) 32/324 (9.9) 19/385 (4.9) 116/1437 (8.1)
 2014- 2015 607/3386 (17.9) 75/324 (23.1) 72/385 (18.7) 234/1437 (16.3)
 2015- 2016 849/3386 (25.1) 59/324 (18.2) 90/385 (23.4) 359/1437 (25.0)
 2016- 2017 996/3386 (29.4) 95/324 (29.3) 125/385 (32.5) 429/1437 (29.9)
aControls from “any influenza” analysis used.
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low precision, the current season VE point estimates against influ-
enza A(H1N1)pdm09 in the 2015/2016 season and against influenza 
A(H3N2) in the seasons where calculable (2011/2012, 2014/2015, 
2016/2017) were lower among those vaccinated in the previous sea-
son than among those not vaccinated in previous season. These VE 
estimates	were	less	than	0%,	suggesting	a	negative	effect	of	previ-
ous vaccination. This was not seen against influenza B, where the VE 
among those previously vaccinated was positive, indicating an effect 
of current vaccination additionally to any residual protection from 
previous vaccination. However, precision is low for most of these 
analyses and the current VE among those vaccinated previously was 
not possible to compute, so we cannot draw conclusions on a con-
sistent or common pattern for the three influenza types/subtypes.
Individuals unvaccinated in both seasons are at a higher risk of 
laboratory- confirmed influenza than in any vaccination scenario 
(current season only, last season only, both seasons). This would sug-
gest that, even if the effect can be limited in some seasons, whatever 
the past vaccination scenario, being vaccinated in a season is always 
beneficial.
In the 2011/2012 and 2016/2017 influenza A(H3N2) seasons 
and in the 2015/2016 influenza A(H1N1)pdm09 analysis, the VE 
point estimates and confidence intervals among those vaccinated 
only in the previous season suggest a protective effect of previous 
season vaccine for those subtypes. This is consistent with the dura-
tion of protection observed for A(H1N1)pdm09, but contradictory to 
the short duration of protection for A(H3N2).21
Our study has several limitations. Even though our analysis is re-
stricted to the target group for vaccination, the vaccination coverage 
is	still	low	(6%,	7%	and	26%	of	controls	vaccinated	in	current	season	
only, in previous season only and in both seasons, respectively). This 
results in a low precision and high variability of the results.
Past infections and natural immunity play an important role in 
the protection against circulating influenza strains 22,23 and may 
strengthen the response to subsequent vaccines.24 Measuring im-
munity conferred by past infection is challenging. An immunological 
study suggests that the response to inactivated influenza vaccines is 
lower among individuals previously vaccinated than among individu-
als with previous natural influenza A(H1N1)pdm09 virus infection.25 
In a hospital- based study in Japan, a negative effect of previous vac-
cination on current season vaccine effectiveness was observed in 
individuals not infected but not in individuals infected with influenza 
A virus in the previous season.8 Individuals in the same age group 
may have had similar exposure to previous circulating influenza vi-
ruses, resulting in a similar influenza antibody landscape.26-28 In our 
study, the low vaccination coverage and number of cases in some 
age groups did not allow for estimation of results by age group.
We only collected information on the effect of one previous 
season vaccination and were not able to take into account the role 
of repeated previous vaccinations. In a study using eight seasons’ 
pooled data and five previous years of historical vaccination, VE 
was similar for those vaccinated in the current season and those 
vaccinated in current and previous seasons.4 However, VE was 
lower for current season in the group of individuals vaccinated at 
least in two of five seasons than in individuals never vaccinated in 
the five seasons.
We documented the vaccine type for the current season but 
not for the previous season. Studies suggest that the type of vac-
cine received in current or previous season may influence the effect 
of previous vaccination in current season VE.4,7 In our study, four 
types of vaccines were used: egg- derived inactivated subunit, egg- 
derived inactivated split virion, cell- derived inactivated subunit and 
adjuvanted vaccines (adjuvant used: squalene (MF59) or aluminium 
phosphate gel). We could not stratify VE results by type of current 
and previous vaccines.
While the test- negative design attempts to control for bias due 
to differential healthcare- seeking behaviours,29 the study is obser-
vational and subject to the usual limitations, in particular adequately 
controlling for confounding.
4.1 | Results interpretation
4.1.1 | Influenza A(H1N1)pdm09
The stratified results in the 2015/2016 season suggested that 
the effectiveness of current season vaccination against influenza 
A(H1N1)pdm09 was lower among those vaccinated in the previous 
season. When using unvaccinated in both seasons as reference, VE 
point estimates for current season vaccination only were higher than 
for both seasons vaccination in three of the four seasons. The posi-
tive VE of previous season vaccination only in the 2014/2015 and 
2015/2016 season analysis suggests a potential residual effect of 
vaccination against influenza A(H1N1)pdm09 in these seasons. This 
observation is in line with two recent meta- analysis11,30 and with the 
stable influenza A(H1N1)pdm09 VE by time since vaccination ob-
served in the I- MOVE MCCS from 2010/2011 to 2015/2016.21
4.1.2 | Influenza A(H3N2)
We observed that in all seasons, A(H3N2) VE point estimates were 
lower among those vaccinated in the previous season than in those 
unvaccinated in previous season.
Using unvaccinated in both seasons as reference, VE of var-
ious vaccination scenarios varied by season. In 2011/2012 and 
2013/2014, VE point estimates against influenza A(H3N2) were 
similar for current season vaccination only and both seasons’ vac-
cination. In 2011/2012, previous and current season vaccine strains 
were antigenically similar but mismatched to one of the cocirculat-
ing strains. In 2013/2014, the circulating strains were antigenically 
similar to the vaccine strain but different to the 2012/2013 vaccine 
strain that had egg- adapted amino acid changes negatively impact-
ing its antigenicity.31
In 2014/2015, VE against influenza A(H3N2) was much lower 
among those vaccinated in 2013/2014 and 2014/2015 than among 
those vaccinated only in 2014/2015. The influenza A(H3N2) vaccine 
strains in 2013/2014 and 2014/2015 were homologous but antigen-
ically different from the drifted virus circulating in 2014/2015. Even 
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if the precision is low, our results are in accordance with the antigenic 
distance hypothesis.16 In the 2014/2015 VE results from Canada5,10 
and from I- MOVE MCCS (not restricted to the target population),6 
the VE point estimate among those vaccinated in both 2013/2014 
and 2014/2015 was negative, suggesting that those vaccinated in 
both seasons were at higher risk of influenza A(H3N2) medically at-
tended influenza than those vaccinated only in 2014/2015. In the 
current I- MOVE MCCS analysis restricted to the vaccine target 
population, the VE point estimate for those vaccinated in both sea-
sons was positive but lower than the VE of those vaccinated only in 
2014/2015.
In 2016/2017, the VE point estimate was also lower for those 
vaccinated in both 2016/2017 and 2015/2016 seasons than in those 
vaccinated only in 2016/2017. The antigenic hypothesis may not 
explain this observation as the A(H3N2) circulating strain and the 
strains included in the 2016/2017 and 2015/2016 vaccines were 
considered antigenically similar. However, it is worth noting that in 
the 2016/2017 season, the A(H3N2) viruses circulating in Europe 
underwent considerable genetic changes with new subgroups diver-
sifying from the vaccine strains.32
4.1.3 | Influenza B
The low precision of the VE against influenza B did not allow us to 
identify any pattern of the effect of previous vaccination. However 
VE point estimates for vaccination in current season only were al-
ways positive and VE point estimates for vaccination in previous 
season only were low or negative. We could not measure VE by 
 influenza B lineage which limits interpretation.
5  | CONCLUSION
We cannot exclude that being vaccinated in the previous season 
may reduce the VE of the current season vaccine, in particular for 
A(H3N2). However, the positive VE results among those vaccinated in 
current season only and those vaccinated in both seasons in this study 
suggest that being vaccinated in a given season is always beneficial.
Despite a growing sample size in I- MOVE MCCS, results are still 
imprecise due to low vaccination coverage and to the strong asso-
ciation between being vaccinated in current season and being vac-
cinated in previous season. The results of the six seasons can only 
contribute to test hypotheses that try to understand the effect of 
previous vaccination on influenza VE.
Influenza vaccine effectiveness depends on complex interactions 
between host (eg natural infection vs vaccination acquired immunity), 
agent and environmental factors.32 Optimum measurement and inter-
pretation of influenza seasonal VE would require taking into account 
many parameters including subtypes, clade, subclades, age, time since 
vaccination, chronic conditions and treatment, duration of protection, 
vaccine types and brands, natural immunity and previous vaccinations.
So far, the studies presenting the effect of previous season in-
fluenza vaccinations neither collected all this information nor were 
powered enough to provide precise results. The modifying or con-
founding effect of those parameters would no longer be relevant in 
terms of public health if the influenza vaccine had a high effectiveness.
Only well- powered, population- based, long prospective studies 
would allow understanding the immunological response to influenza 
vaccinations and infections. They could document influenza infec-
tions, vaccinations and type of vaccines used, cellular and humoural 
immune status before and during each season in vaccinated and 
unvaccinated, infected and not. A European mechanism of funding 
such large studies is needed to ensure powerful studies conducted 
independently from funding sources.
In the context of universal influenza vaccine development, the 
question is whether results of these proposed prospective stud-
ies would be available before the next generation of vaccines is 
accessible.
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